% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • cvarg4 cvarg4 Apr 26, 2014 3:53 PM Flag

    Hear on the street

    A failed study is a failed study, regardless of the spin applied. You can't argue the statistical significance of a secondary endpoint when the primary endpoint doesn't work, especially when that endpoint was designed to make the drug look better. There is no way FDA will approve Arikayce without Insmed conducting another study using culture conversion as the primary endpoint, especially since the antibiotic yielded questionable data in a previous study involving cystic fibrosis patients.

17.43+0.31(+1.81%)Oct 9 4:00 PMEDT